J&J makes $1B move for Firefly Bio, Carolyn Bertozzi's twist on ADCs in KRAS field
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader...
Johnson & Johnson is making another early-stage oncology deal, dishing out $1 billion in cash to acquire Firefly Bio, a preclinical startup working on degrader antibody conjugates. J&J now joins the 2026 pharma dealmaking frenzy ...